You are here: Industry Insights > Oramed

News List

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials drugs
August 25, 2021
Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
Oramed Initiates Second Phase 3 Oral Insulin Study americanpharmaceuticalreview
March 30, 2021
Oramed Pharmaceuticals has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Premas Biotech, Oramed announce single-dose oral COVID-19 vaccine candidate expresspharma
March 22, 2021
Premas Biotech announced the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals.
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study americanpharmaceuticalreview
January 27, 2021
Oramed Pharmaceuticals announced randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way.
Oramed Initiates Phase 3 Trial of Oral Insulin americanpharmaceuticalreview
December 11, 2020
Oramed Pharmaceuticals has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
Oramed Initiates NASH Trial of Oral Insulin americanpharmaceuticalreview
December 03, 2020
Oramed Pharmaceuticals has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH).
Oramed Reports Positive End of Phase 2 Meeting with the FDA for Oral Insulin americanpharmaceuticalreview
July 24, 2020
Oramed Pharmaceuticals announced the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801).
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule americanpharmaceuticalreview
September 20, 2018
Oramed Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901.
Oramed gets Japanese Patent for GLP-1 analog capsule biospectrumasia
July 25, 2018
A Japanese Intellectual Property Office has publicized its intent to grant a patent titled, "Methods and Compositions for Oral Administration of Exenatide"
Oramed Initiates 90-Day Clinical Study for Oral Insulin americanpharmaceuticalreview
April 24, 2018
Oramed Pharmaceuticals has begun screening patients in its 90-day dose-ranging Pivotal Phase 2b HbA1c clinical study of its oral insulin capsule, ORMD-0801.

Previous page 1 2 Next page